Home » Clinical Trials » Search Clinical Trials
Parent Therapeutic Areas: Oncology | Obstetrics/Gynecology | Endocrinology

Ovarian Cancer

Arizona

Peoria : Merck

Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals

California

Anaheim : Pacific Cancer Medical Center

Research Study of Carboplatin and DOXIL plus Bevacizumab in Patients with Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers

Anaheim : Pacific Cancer Medical Center

Research Study of Carboplatin and DOXIL plus Bevacizumab in Patients with Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers

Corona : Compassionate Cancer Care Medical Group

Research Study of Carboplatin and DOXIL plus Bevacizumab in Patients with Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers

Corona : Compassionate Cancer Care Medical Group

Research Study of Carboplatin and DOXIL plus Bevacizumab in Patients with Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers

Duarte : City of Hope New!

Integration of Palliative Care in Use of Intra-Peritoneal Chemotherapy for Ovarian Cancer

Duarte : City of Hope New!

Randomized Pilot Trial of Oral Cyclophosphamide versus Oral Cyclophosphamide with Celecoxib for Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Fountain Valley : Compassionate Cancer Care Medical Group

Research Study of Carboplatin and DOXIL plus Bevacizumab in Patients with Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers

Fountain Valley : Compassionate Cancer Care Medical Group

Research Study of Carboplatin and DOXIL plus Bevacizumab in Patients with Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers

Los Angeles : Merck

Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals

Newport Beach : Gynecologic Oncology Associates

Research Study of Carboplatin and DOXIL plus Bevacizumab in Patients with Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers

Newport Beach : Gynecologic Oncology Associates

Research Study of Carboplatin and DOXIL plus Bevacizumab in Patients with Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers

Pleasant : Bay Area Cancer Research Group

Research Study of Carboplatin and DOXIL plus Bevacizumab in Patients with Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers

Pleasant : Bay Area Cancer Research Group

Research Study of Carboplatin and DOXIL plus Bevacizumab in Patients with Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers

Riverside : Compassionate Cancer Care Medical Group

Research Study of Carboplatin and DOXIL plus Bevacizumab in Patients with Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers

Riverside : Compassionate Cancer Care Medical Group

Research Study of Carboplatin and DOXIL plus Bevacizumab in Patients with Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers

Colorado

Denver : Merck

Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals

Englewood : Rocky Mountain Gynecologic Oncology

Research Study of Carboplatin and DOXIL plus Bevacizumab in Patients with Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers

Englewood : Rocky Mountain Gynecologic Oncology

Research Study of Carboplatin and DOXIL plus Bevacizumab in Patients with Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers

Florida

Hialeah : Merck

Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals

New Port Rich : Research Center

Research Study of Carboplatin and DOXIL plus Bevacizumab in Patients with Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers

New Port Rich : Research Site

Research Study of Carboplatin and DOXIL plus Bevacizumab in Patients with Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers

West Palm Beach : Palm Beach Cancer Center

Phase 2 study to evaluate the efficacy and safety of NKTR 102 (PEG-Irinotecan) when given on a Q14 day or a Q21 day schedule in patients with metastatic or locally advanced platinum-resistant ovarian cancer

Georgia

Athens : Northeast Georgia Cancer Care, LLC

Research Study of Carboplatin and DOXIL plus Bevacizumab in Patients with Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers

Athens : Northeast Georgia Cancer Care, LLC

Research Study of Carboplatin and DOXIL plus Bevacizumab in Patients with Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers

Athens : Southeastern Gynecologic Oncology

Research Study of Carboplatin and DOXIL plus Bevacizumab in Patients with Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers

Atlanta : Southeastern Gynecologic Oncology

Research Study of Carboplatin and DOXIL plus Bevacizumab in Patients with Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers

Augusta : Medical College of Georgia

Research Study of Carboplatin and DOXIL plus Bevacizumab in Patients with Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers

Augusta : Medical College of Georgia

Research Study of Carboplatin and DOXIL plus Bevacizumab in Patients with Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers

Savannah : Memorial Health University Medical Center

Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II or Stage III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer GOG 0252

Savannah : Memorial Health University Medical Center

ChemoFx® Observational Study in Gynecological Solid Tumors

Savannah : Memorial Health University Medical Center

Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse

Savannah : Memorial Health University Medical Center

GOG-136: Acquisition of human gynecologic specimens and serum to be used in studying the causes, diagnosis, prevention and treatment of cancer

Savannah : Memorial Health University Medical Center

Paclitaxel in Treating Patients With Ovarian Stromal Cancer GOG 187

Savannah : Memorial Health University Medical Center

Paclitaxel or Polyglutamate Paclitaxel or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Peritoneal Cancer or Fallopian Tube Cancer GOG 0212

Savannah : Memorial Health University Medical Center

Surgery and Combination Chemotherapy in Treating Children With Extracranial Germ Cell Tumors AGCT0132

Illinois

Chicago : Merck

Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals

Chicago : Merck

Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals

Gurnee : Oncology Hematology Associates of Northern Illinois

Research Study of Carboplatin and DOXIL plus Bevacizumab in Patients with Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers

Gurnee : Oncology Hematology Associates of Northern Illinois

Research Study of Carboplatin and DOXIL plus Bevacizumab in Patients with Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers

Hines : Merck

Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals

Indiana

Beech Grove : St. Francis Hospital and Health Centers

A Study of Carboplatin and Gemcitabine Plus Bevacizumab in Patients With Ovary, Peritoneal, or Fallopian Tube Carcinoma (OCEANS)

Kansas

Witcha : Cancer Center of Kansas

Research Study of Carboplatin and DOXIL plus Bevacizumab in Patients with Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers

Witcha : Cancer Center of Kansas

Research Study of Carboplatin and DOXIL plus Bevacizumab in Patients with Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers

Missouri

Saint Louis : Merck

Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals

New Jersey

Morristown : Atlantic Health System

A Study Comparing the Combination of Doxil and Yondelis, to Doxil Alone for Subjects With Ovarian Cancer

Morristown : Atlantic Health System

A Study of Carboplatin and Gemcitabine Plus Bevacizumab in Patients With Ovary, Peritoneal, or Fallopian Tube Carcinoma (OCEANS)

Morristown : Atlantic Health System

A Study to Evaluate the Safety, Tolerability, and Activity of Lonafarnib and Docetaxel (Study P04467AM1)

Newark : Merck

Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals

New York

Brightwaters : Biomedical Research Alliance of New York

Safety and Effectiveness of an Experimental drug for Reducing the Side-Effects of Chemotherapy Given for Recurrent Ovarian Cancer – Adults

Bronx : Biomedical Research Alliance of New York

Abnormal Pelvic Mass - Adults

Bronx : Einstein-Montefiore Institute for Clinical & Translational Research

Phase II Study of Paclitaxel for Ovarian Stromal Tumors as First-line and Second-line Therapy

East Syracuse : Merck

Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals

New York : Mount Sinai Medical Center

A Phase II Evaluation of Lapatinib (GW572016) (NCI-Supplied Agent, NSC #727989, IND #70,252) in the Treatment of Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma [GOG-0170-G]

New York : Mount Sinai Medical Center

A Phase II Evaluation of Triapine (NCI-Supplied Agent: NSC #663249, IND #68338)) in Combination with Cisplatin (Commercially Available: NSC #119875) in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian or Primary Peritoneal Carcinoma [GOG 0126-o]

New York : Mount Sinai Medical Center

A Phase II Randomized Study of the Effect of Zoledronic Acid Versus Observation on Bone Mineral Density of the Lumbar Spine in Woman who Elect to Undergo Risk-Reducing Surgery that Results in Removal of Both Ovaries [GOG0215]

New York : Mount Sinai Medical Center

A Randomized Study of Tamoxifen Versus Thalidomide (NSC# 66847) in Patients with Biochemical-Recurrence-Only-Epithelial Ovarian Cancer, Cancer of the Fallopian Tube, and Primary Peritoneal Carcinoma After First Line Chemotherapy [GOG-0198]

New York : Mount Sinai Medical Center

An Exploratory Evaluation of Fenretinide (4-HPR) (IND #39,812) as a Chemopreventive Agent for Ovarian Carcinoma [GOG0190]

New York : Mount Sinai Medical Center

Prospective Study of Risk-Reducing Salpingo-Ophorectomy and Longitudinal CA-125 Screening Among Women at Increased Genetic Risk of Ovarian Cancer [GOG 0199]

Rochester : Merck

Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals

North Dakota

Bismarck : Legacy Pharma Research

Advanced Ovarian Cancer

Oklahoma

Tulsa : Cancer Care Associates

Research Study of Carboplatin and DOXIL plus Bevacizumab in Patients with Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers

Tulsa : Cancer Care Associates

Research Study of Carboplatin and DOXIL plus Bevacizumab in Patients with Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers

Rhode Island

Providence : Merck

Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals

Tennessee

Chattanooga : Tennessee GYN Oncology Group, LLC

Research Study of Carboplatin and DOXIL plus Bevacizumab in Patients with Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers

Chattanooga : Tennessee GYN Oncology Group, LLC

Research Study of Carboplatin and DOXIL plus Bevacizumab in Patients with Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers

Knoxville : Hall and Martin MDs, PC

Research Study of Carboplatin and DOXIL plus Bevacizumab in Patients with Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers

Knoxville : Hall and Martin MDs, PC

Research Study of Carboplatin and DOXIL plus Bevacizumab in Patients with Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers

Texas

Amarillo : Harrington Cancer Center

Research Study of Carboplatin and DOXIL plus Bevacizumab in Patients with Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers

Amarilo : Harrington Cancer Center

Research Study of Carboplatin and DOXIL plus Bevacizumab in Patients with Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers

Austin : Southwest Regional Cancer Center

Research Study of Carboplatin and DOXIL plus Bevacizumab in Patients with Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers

Austin : Southwest Regional Cancer Center

Research Study of Carboplatin and DOXIL plus Bevacizumab in Patients with Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers

Houston : Merck

Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals

Houston : S. R. Burzynski Clinic

Phase II Study Of Antineoplastons A10 And AS2-1 In Patients With Carcinoma Of The Ovary

Houston : S. R. Burzynski Clinic

Phase II Study Of Antineoplastons A10 And AS2-1 In Patients With Carcinoma Of The Uterine Cervix And/Or Vulva

Houston : S. R. Burzynski Clinic

Phase II Study Of Antineoplastons A10 And AS2-1In Patients With Adenocarcinoma Of The Stomach

San Antonio : South Texas Oncology & Hematology PA

Research Study of Carboplatin and DOXIL plus Bevacizumab in Patients with Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers

San Antonio : South Texas Oncology & Hematology PA

Research Study of Carboplatin and DOXIL plus Bevacizumab in Patients with Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers

Virginia

Charlottesville : University of Virginia

Women ages 18 and above at high risk for Ovarian Cancer planning to undergo removal of both ovaries needed for research study.

Charlottesville : University of Virginia

Women who plan to have their ovaries removed sought for research study.

Charlottesville : University of Virginia

Women with Ovarian or Peritoneal Cancer Sought for Research Study.

Washington

Olympia : Capital Oncology, PLLC

Research Study of Carboplatin and DOXIL plus Bevacizumab in Patients with Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers

Olympia : Capital Oncology, PLLC

Research Study of Carboplatin and DOXIL plus Bevacizumab in Patients with Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers

Seattle : Merck

Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals

Australia

South Granville : Merck Sharp & Dohme (Australia) Pty Ltd.

Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals

Belgium

Bruxelles : Research Site:

A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer

Leuven : Research Site:

A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer

Wilrijk : Research Site:

A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer

Brazil

Jaú : Research Site:

A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer

Sao Paulo : Research Site:

A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer

Canada

Calgary, AB : Research Site:

A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer

Kelowna, BC : Research Site:

A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer

Vancouver, BC : Research Site:

A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer

Denmark

Herlev : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

København : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Odense : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

France

Ales : Research Site:

A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer

Ales : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Amiens : Research Site:

A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer

Avignon : Research Site:

A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer

Avignon : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Bordeaux : Research Site:

A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer

Bordeaux : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Brive : Research Site:

A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer

Brive : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Caen : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Clamart : Research Site:

A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer

Colmar : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Dax : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Dijon : Research Site:

A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer

Gap : Research Site:

A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer

Grenoble : Research Site:

A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer

Grenoble : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

La Roche Sur Yon : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Le Chesnay : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Le Mans : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Lille : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Lyon : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Marseille : Research Site:

A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer

Mont-De-Marsan : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Montpellier : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Mougins : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Nancy : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Nantes : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Nice : Research Site:

A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer

Nice : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Nimes : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Orleans : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Paris : Research Site:

A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer

Paris : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Perigueux : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Poitiers : Research Site:

A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer

Pringy : Research Site:

A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer

Pringy : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Reims : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Rouen : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Saint Brieuc : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Saint Herblain : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Saint Nazaire : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Saint-Cloud : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Saint-Priest-En-Jarez : Research Site:

A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer

St Cloud : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Strasbourg : Research Site:

A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer

Strasbourg : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Thonon-Les-Bains : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Toulouse : Research Site:

A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer

Valenciennes : Research Site:

A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer

Vandoeuvre-Les-Nancy : Research Site:

A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer

Vandoeuvre-Les-Nancy : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Germany

Berlin : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Bremen : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Düsseldorf : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Erlangen : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Essen : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Frankfurt Am Main : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Hamburg : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Hannover : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Hildesheim : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Kassel : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Kiel : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Krefeld : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Lübeck : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Mannheim : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

München : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Nürnberg : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Offenbach : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Recklinghausen : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Rostock : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Solingen : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Stuttgart : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Tübingen : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Ulm : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Wiesbaden : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Hungary

Budapest : Research Site:

A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer

Debrecen : Research Site:

A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer

Gyor : Research Site:

A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer

Italy

Aviano : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Bergamo : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Campobasso : Research Site:

A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer

Milano : Research Site:

A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer

Milano : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Modena : Research Site:

A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer

Napoli : Research Site:

A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer

Palermo : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Parma : Research Site:

A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer

Roma : Research Site:

A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer

Roma : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Torino : Research Site:

A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer

Trento : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Udine : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Netherlands

Alkmaar : Research Site:

A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer

Amsterdam : Research Site:

A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer

Amsterdam : Research Site:

A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer

Apeldoorn : Research Site:

A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer

Enschede : Research Site:

A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer

Groningen : Research Site:

A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer

Leiden : Research Site:

A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer

Leidschendam : Research Site:

A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer

Tilburg : Research Site:

A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer

Zwolle : Research Site:

A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer

Norway

Bergen : Research Site:

A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer

Bergen : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Oslo : Research Site:

A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer

Oslo : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Trondheim : Research Site:

A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer

Poland

Gdansk : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Poznan : Research Site:

A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer

Poznan : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Warszawa : Research Site:

A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer

Warszawa : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Portugal

Lisboa : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Porto : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Russian Federation

Kazan : Research Site:

A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer

Krasnodar : Research Site:

A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer

Moscow : Research Site:

A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer

Moscow : Research Site:

A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer

Obninsk, Kaluzhskaya Region : Research Site:

A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer

St Petersburg : Research Site:

A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer

Stavropol : Research Site:

A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer

Tomsk : Research Site:

A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer

Spain

Barcelona : Research Site:

A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer

Barcelona : Research Site:

A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer

Barcelona : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Córdoba : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Lerida : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Madrid : Research Site:

A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer

Madrid : Research Site:

A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer

Madrid : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Málaga : Research Site:

A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer

Murcia : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Palma de Mallorca : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Sabadell : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Sevilla : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Terrassa : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Valencia : Research Site:

A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer

Valencia : Research Site:

A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer

Valencia : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Zaragoza : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Sweden

Goeteborg : Research Site:

A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer

Göteborg : Research Site:

A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer

Linkoeping : Research Site:

A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer

Linkoeping : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Örebro : Research Site:

A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer

Örebro : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Umea : Research Site:

A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer

Umea : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Uppsala : Research Site:

A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer

Uppsala : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Switzerland

Chur : Research Site:

A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer

St Gallen : Research Site:

A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer

Turkey

Adana : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Istanbul : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Kocaeli : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

United Kingdom

Birmingham : Research Site:

A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer

London : Research Site:

A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer

London : Research Site:

A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer

Manchester : Research Site:

A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer

Plymouth : Research Site:

A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer

Sutton : Research Site:

A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer

Yeovil : Research Site:

A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer